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Abstract
Background
Adverse events (AEs) of second line anti-tuberculosis drugs (SLDs) are relatively well docu-
mented. However, the actual burden has rarely been described in detail in programmatic
settings. We investigated the occurrence of these events in the national cohort of multidrug-
resistant tuberculosis (MDR-TB) patients in Nigeria.
Method
This was a retrospective, observational cohort study, using pharmacovigilance data sys-
tematically collected at all MDR-TB treatment centers in Nigeria. Characteristics of AEs dur-
ing the intensive phase treatment were documented, and risk factors for development of
AEs were assessed.
Results
Four hundred and sixty patients were included in the analysis: 62% were male; median age
was 33 years [Interquartile Range (IQR):28–42] and median weight was 51 kg (IQR:
45–59). Two hundred and three (44%) patients experienced AEs; four died of conditions as-
sociated with SLD AEs. Gastro-intestinal (n = 100), neurological (n = 75), ototoxic (n = 72)
and psychiatric (n = 60) AEs were the most commonly reported, whereas ototoxic and psy-
chiatric AEs were the most debilitating. Majority of AEs developed after 1–2 months of ther-
apy, and resolved in less than a month after treatment. Some treatment centers were twice
as likely to report AEs compared with others, highlighting significant inconsistencies in
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reporting at different treatment centers. Patients with a higher body weight had an increased
risk of experiencing AEs. No differences were observed in risk of AEs between HIV-infected
and uninfected patients. Similarly, age was not significantly associated with AEs.
Conclusion
Patients in the Nigerian MDR-TB cohort experienced a wide range of AEs, some of which
were disabling and fatal. Early identification and prompt management as well as standard-
ized reporting of AEs at all levels of healthcare, including the community is urgently needed.
Safer regimens for drug-resistant TB with the shortest duration are advocated.
Introduction
Multidrug-resistant tuberculosis (MDR-TB) (Tuberculosis that is resistant to at least Rifampi-
cin and Isoniazid) is a growing clinical and public health problem worldwide [1, 2]. Treatment
takes a total duration of 20 months (8 months intensive phase inclusive) of administration of
second line anti-tuberculosis drugs (SLDs), which are associated with a wide range of adverse
drug reactions (ADRs) [3,4]. In recent times, such ADRs have become a source of global public
health concern, since they significantly contribute to morbidity, mortality, losses to follow-up
and increased health care costs [3–7]. In resource-limited settings, the consequences of ADRs
is alarming because the health facilities and specialist services required for the management are
scarce; hence, treatment interruptions, adherence difficulties, loss to follow up, treatment fail-
ure and as a consequence, the emergence of further drug resistance [6–9] are expected. For this
reason, the World Health Organization (WHO) has recommended the aggressive management
of ADRs as an essential component of the care of MDR-TB patients [10].
Nigeria’s total population in 2014 was above 170 million people spread across 36 states and
the Federal Capital Territory (FCT) [11]. Approximately 50% of the total population lives in
urban areas. In 2014, the population growth rate and life expectancy at birth for the total popu-
lation were 2.47% and 52.62 years respectively. Hospital bed density in 2004 was 0.53 beds per
1000 population, while maternal mortality rate was 630 deaths per 100,000 live births in 2014
[11]. Infant mortality rate was 74.04 deaths per 1,000 live births in 2014[11]. In the midst of
HIV/AIDS epidemics, MDR-TB has emerged as a significant public health problem. The 2012
National Drug Resistant Tuberculosis Prevalence Survey (NDRPS) revealed a growing popula-
tion of people living with MDR-TB. At least, 2.9% of reported MDR-TB cases were from new
TB patients while 14.3% were from previously treated TB patients [2, 12]. However, according
to government sources, notable achievements have been recorded in controlling the epidemic.
Some of these achievements include the development of the Nigerian MDR-TB National Treat-
ment Guidelines [13], the award of the Global Fund Round 9 grant (GFR9) for the control of
MDRTB and case management of MDR-TB patients at health facilities up to the Local Govern-
ment Areas (LGAs) level.
Drug-susceptible TB patients, including those with a previous history of TB treatment, initi-
ate treatment with first-line anti-TB drugs at one of the 3,455 health facilities in Nigeria [14].
Once these patients are diagnosed with MDR-TB, they are registered and referred to the MDR-
TB treatment centers by the national tuberculosis and leprosy control program (NTBLCP)
after being educated on the need for long hospitalization and have signed informed consent
forms. There were nine functional MDR-TB centers spread across seven states as of 31st March
2014. The number of treatment centers is however expected to multiply in the next few years
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because the GeneXpert MTB/RIF technology, which facilitates early detection of MDR-TB
among patients in high risk group, has been introduced. In 2013, there are over 64 GeneXpert
POCMachines for molecular diagnosis, distributed all over the states.
Despite the remarkable achievements that have been recorded, there is no published report
on the AEs associated with the SLDs in Nigeria. Local studies have focused on issues related to
the under-reporting of the AEs to the National Pharmacovigilance Center (NPC) [15–18] with-
out assessing the actual burden of AEs, and as a result, there is a paucity of AEs data to promote
patient care as well as national drug safety surveillance. At the global level, the few studies that
have reported the AEs of the SLDs included low numbers of participants from individual treat-
ment centers, which limited the generalizability of the studies [19–21]. Our study has addressed
these gaps in knowledge in two main ways: we relied on the national cohort of MDR-TB pa-
tients from the nine treatment centers, and assessed the actual burden of AEs during the inten-
sive phase of treatment over a period of two years. The objectives of the study were to
document the incidence, types, time of occurrence, and duration of AEs among MDR-TB pa-
tients during the intensive phase of treatment and their risk factors.
Methods
Definition of terms
In describing the consequences of the SLDs, we utilized two terms: “adverse drug reactions”
and “adverse event”. Adverse drug reaction (ADR) according to the WHO, is any noxious and
unintended response to a drug that occurs at doses normally used in man to prevent, diagnose,
or treat disease or to modify physiological function [5], while “adverse event” (AE) refers to:
(1) Any untoward medical occurrence in a patient or clinical investigation subject given a phar-
maceutical product; does not necessarily have a causal relationship with such treatment; and
(2) Any unfavorable and unintended sign (including abnormal laboratory findings), symptom,
or disease temporally associated with the use of a medicinal (investigational) product; not nec-
essarily related to the product [22].
Ethics
Ethical approval was given by the Health Research Ethics Committee of the Institute of
Human Virology Nigeria in collaboration with the National Health Research Ethics Committee
of Nigeria in August, 2013. This study has also met the Médecins Sans Frontières Ethics Review
Board (Geneva, Switzerland) approved criteria for analysis of routinely-collected program data
in August, 2013. It satisfies the requirements of the Ethics Advisory Group of the International
Union Against Tuberculosis and Lung Disease, Paris, France. Patient information was anon-
ymized and de-identified prior to analysis. As this was a routinely collected program data, in-
formed consent from the patients was not obtained. The named ethics committees approved
the study and waived the need for consent.
Study design
This was a retrospective, observational cohort study, using pharmacovigilance data systemati-
cally collected at all MDR-TB treatment centers in Nigeria.
Study population
All MDR-TB patients starting the intensive phase treatment at all MDR-TB treatment centers
in Nigeria, from 1st February 2012 to 31st December 2013, were included in the study.
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Setting
MDR-TB Program in Nigeria. Treatment of MDR-TB consists of an intensive and a continua-
tion phase under direct observation of trained health care providers. The intensive phase is
strictly hospital-based during which patients are admitted and given a standard regimen con-
sisting of Kanamycin (Km) or Amikacin (Amk), Pyrazinamide (Z), Levofloxacin (Lfx), Cyclo-
serine (Cs), Prothionamide (Pto) and Pyridoxine, for at least eight months. This is followed by
twelve months of continuation phase during which patients take Pyrazinamide (Z), Levofloxa-
cin (Lfx), Cycloserine (Cs), Prothionamide (Pto) and Pyridoxine.
Clinical and bacteriological monitoring using sputum smear/culture tests is performed
monthly during the intensive phase and bimonthly during the continuation phase. A patient is
considered sputum smear or culture negative when results of two consecutive results are nega-
tive. Patients are discharged to the community where they are followed up on a regular basis at
the end of the intensive phase. However, patients who remain culture positive at the end of the
intensive phase, continue with the intensive phase treatment.
Diagnosis of adverse events
AEs were diagnosed by the treatment centers through a combination of direct observation, lab-
oratory report and participant’s reports—these methods are recommended by the international
conference on harmonization (ICH) [22–24]. In the direct observation, a trained health worker
(usually a clinician) physically examined the patient, while the laboratory reports involved con-
ducting specific laboratory tests to diagnose or confirm a suspected AE. Participants’ reports
involved the patients reporting the AEs they experienced to the health workers while on admis-
sion. Because of the subjective nature of the participants’ reports, clinicians requested for fur-
ther investigations but the decision was entirely at the discretion of the clinician.
Grouping and severity of adverse events
The AEs were grouped into 11 major classes based on recommendations from experts and ICH
guidelines (Table 1).
The grouping of the AEs became necessary because patients took more than one drug and
each drug presented with several AEs. We also categorized the severity of the AEs into 6 cate-
gories based on signs and symptoms (Table 2).
Reporting of AEs at the treatment centers
Suspected AEs were reported in the “Yellow Form” (Fig. 1) [also known as the Pharmacovigi-
lance Form (PVG)] through the spontaneous reporting systems (SRS) [25–27]. The SRS is
managed nationally by the National Pharmacovigilance Center located in the head office of the
National Agency for Food and Drug Administration Control (NAFDAC) in Abuja.
The completed forms were collected and signed by the pharmacists and then dispatched as
individual case safety reports (ICSRs) [28] to the NTBLCP, NPC and the Institute of Human
Virology, Nigeria. In this study, we focused on AEs reported during the intensive phase since
the patients were on admission at this time and were under observation by the health workers.
Data collection and analysis
We collected the following variables from the completed PVG forms: unique patient identifica-
tion number, age, gender, body weight, treatment centers, patient HIV status and AEs. We also
collected the date of start of treatment; date of onset and duration of AEs for patients whose
AEs had been treated and resolved at the time of data collection. The outcomes at the end of
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the intensive phase (completion of the intensive phase treatment, absconding from treatment
and death) were also collected. We applied summary statistics to describe socio-demographic
and treatment characteristics, while associations between the occurrence of AE and demo-
graphic and clinical characteristics were explored through multivariate logistic regression using
a stepwise backward elimination approach; p-values based on Wald’s test are indicated.
Results
Of the 473 MDR-TB patients who were registered for the intensive phase treatment during the
review period, 13 (3%) were wrongly diagnosed as having MDR-TB, and were excluded from
further analysis. Among the 460 included patients, 203 (44%) experienced AEs.
Patient and adverse events characteristics
The socio-demographic and treatment characteristics are presented in Table 3. Male partici-
pants represented 62%; median age and weight were 33 years and 51 kg respectively. Ten per-
cent of the patients were co-infected with the Human Immunodeficiency Virus (HIV).
Table 1. Grouping of adverse events of second—line anti-tuberculosis drugs.
CATEGORY ADVERSE EVENTS
OTOTOXICITY Tinnitus, Hearing loss, Deafness, Disequilibrium, Vertigo
PSYCHIATRIC Irritability, Anxiety, Depression, Suicidal Ideation, Personality Changes, Depression, Psychosis,
NEUROLOGICAL Dizziness, Insomnia, Vertigo, Convulsion, Syncope, Peripheral neuropathy, Blurring of Vision, Parasthesia,
Fasciculation, Numbness, Incoherent speech, Oculogyric syndrome, Seizures, Palpitation, Atrophy at injection site
ENDOCRINE Poor glycemic control, Hypothyroidism
DERMATOLOGICAL Skin pigmentation, Photosensitivity, Dry skin, Stevens-Johnson syndrome, Fungal Infection, Itching, Skin reaction,
Urticaria
GASTROINTESTINAL Nausea, Vomiting, Gastritis, Ulcers, Hepatitis, Bowel obstruction, Abdominal discomfort, Gastrointestinal bleeding,
Abdominal pain, Abdominal upset, Anorexia, Diarrhea, Dyspepsia, Hepatotoxicity
ELECTROLYTE
ABNORMALTIES
Dehydration, Hypocalcaemia, Hypomagnesaemia, Hypokalaemia
NEPHROLOGICAL Renal Insufﬁciency
ALLERGIC Allergic reactions
ARTHRALGIA Joint pain, Ankle swelling and pains, Arthritis, Myalgia, Stiffness of ﬁngers
GENERAL BODY PAIN Pain in the lower back, headache, pain at injection site, Generalized body pain, musculoskeletal pain, Pain radiating to
the back.
OTHERS Weight loss, Vaginal discharges, Anemia, Body weakness, Palpitation, Fever, Hair loss, Bitterness of mouth, Heart
failure, Hypertension, No menstruation, Pains in the legs, Restlessness, Tendinitis, Unstable temperature.
doi:10.1371/journal.pone.0120161.t001
Table 2. Categorizing of adverse events based on signs and symptoms.
None No signs/symptoms or within normal limits
Mild Minor signs/symptoms; no speciﬁc medical intervention required; asymptomatic
laboratory ﬁndings only, radiographic ﬁndings only; marginal clinical relevance
Moderate Requiring minimal, local, or noninvasive intervention only
Severe Signiﬁcant symptoms requiring hospitalization or invasive intervention
Life-threatening or
disabling
Complicated by acute, life-threatening metabolic or cardiovascular
complications (such as circulatory failure, hemorrhage, sepsis); life-threatening
physiological consequences; or need for intensive care or emergent invasive
procedure
Fatal Causing death
doi:10.1371/journal.pone.0120161.t002
Adverse Events of Second Line Anti-Tuberculosis Drugs in Nigeria
PLOS ONE | DOI:10.1371/journal.pone.0120161 March 17, 2015 5 / 15
Fig. 2 shows the occurrence of the AEs and their severities; four patients died as a conse-
quence of conditions associated with AEs (gastrointestinal = 2 deaths; electrolyte imbalance =
1 death and others (heart failure) = 1 death). Gastro-intestinal AEs were most commonly re-
ported, followed by neurological, ototoxic and psychiatric AEs.
The most debilitating AEs were ototoxic and psychiatric events. In terms of timing of AEs
occurrence, the first AE to appear were allergic reactions (at a median time of 20 days, IQR
5–81), while adverse events related to electrolyte imbalances took a longer time to appear (me-
dian 174 days, IQR 105–201) (Fig. 3).
In terms of duration, most AEs resolved in less than three weeks after onset (median 13
days, IQR 5–29) (Fig. 4).
At the end of the eight month intensive phase treatment, among the 373 patients with a fol-
low up>8 months, 327 (88%) patients were alive; 21 (6%) died with the MDRTB while on
treatment; 4 (1%) absconded without being discharged; 2 (1%) were discharged against medical
advice and 2 (1%) developed extensively drug resistant tuberculosis (XDR-TB).
Fig 1. Pharmacovigilance Form (Yellow Form).
doi:10.1371/journal.pone.0120161.g001
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Factors associated with adverse events
Potential associations between AEs and socio-demographic and/or clinical factors were ana-
lyzed: bivariate and multivariate analysis was performed. The same variables were identified as
significant in bivariate and multivariate analysis; only the results of the multivariate analysis
are shown (Table 4). Compared to the treatment center at the Maryland Hospital Yaba
(MHY), the Dr Lawrence Memorial Hospital (DLMH) and University of Port Harcourt Teach-
ing Hospital (UPTH) centers were more likely to report AEs [respectively OR 5.8 (95% CI 2.6–
12.9; p<0.001) and OR = 8.6 (95%CI 3.0–24.1; p<0.001)]. Patients with a body weight of 61 kg
to 90 kg had higher risk of AEs compared to patients with a body weight of 30 kg to 60 kg [OR
Table 3. Baseline characteristics of MDR-TB patients admitted to in-patient care, Nigeria, 2012–2013
(N = 482).
Variable Number (%)
TOTAL 460
Treatment center
Dr. Lawrence Henshaw Memorial Hospital, Calabar 51 (11)
General Chest Hospital, Ibadan 82 (18)
Infectious Disease Hospital, Kano 40 (9)
Jos University Teaching Hospital, Jos 29 (6)
Mainland Hospital, Yaba 97 (21)
National Tuberculosis and Leprosy Training Center 41 (9)
University College Hospital, Ibadan 69 (15)
University of Port Harcourt Teaching Hospital 38 (8)
University of Uyo Teaching Hospital, Uyo 13 (3)
Age (Years)
<15 6 (1)
15–25 79 (17)
26–35 187 (41)
36–45 98 (21)
46–55 60 (13)
56–65 23 (5)
>65 5 (1)
Not recorded 2 (0.4)
Median (IQR) 33 (28–42)
Gender
Male participants 285 (62)
Female participants 172 (37)
Unknown 3 (1)
Weight (Kg)
<25 6 (1)
25–30 4 (1)
31–60 355 (77)
61–90 94 (20)
Unknown 1 (0.2)
Median (IQR) 51 (45–59)
HIV status
Negative 413 (90)
Positive 47 (10)
doi:10.1371/journal.pone.0120161.t003
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Fig 2. Number and severity of adverse events amongMDR-TB patients in Nigeria, 2012–2013 (N = 482).
doi:10.1371/journal.pone.0120161.g002
Fig 3. ADRs and time of onset among MDR-TB patients admitted to in-patient care, Nigeria, 2012–2013.
doi:10.1371/journal.pone.0120161.g003
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2.0 (95% CI 1.2–3.4; p = 0.008]. No increased risk of AEs was observed among HIV infected
patients and no statistical associations were found between the AEs and intensive phase out-
comes. We also did not observe any association between the AEs and age.
Discussion
This is the first study to report the burden of AEs of SLDs in Nigeria, even though the nation
has been treating patients using these medications since June 2010 [14]. Previously published
studies on MDR-TB focused either on the prevalence of MDR-TB or MDR-TB treatment out-
comes, without evaluating the occurrence of AEs in great detail [29, 30]. We show a consider-
able burden of AEs in the MDR-TB population, with almost half suffering from AEs and many
experiencing severe, debilitating and even fatal events.
Our study has four important findings. Firstly, we reported a wide range of AEs among the
participants, which confirmed existing knowledge on the toxicity of SLDs reported in several
studies ([3, 16, 17] and [31]). This finding echoes the overriding importance of managing AEs
concurrently with MDR-TB treatment, which the WHO has stressed [8]. Secondly, we have
identified the frequently experienced AEs in the Nigerian cohort (gastrointestinal, ototoxic,
psychiatric and neurological); health workers should be alert for these AEs. Thirdly, we found
significant variations in the reporting of AEs among the treatment centers, suggesting the need
for standardization in training for all health staff. Fourthly, co-infection with HIV did not sig-
nificantly increase the risk of AEs, which is consistent with findings from other studies
([19, 20] and [32]). We also found a high rate of patient survival and retention in care, which
Oladimeji et al. [30] also reported.
The study had several strengths: it was country wide, and findings are thus likely to be gen-
eralizable. Additionally, we adhered to the STROBE guidelines [33]. However, we also faced
some limitations: health workers may have wrongly diagnosed some AEs, which potentially af-
fected the magnitude of the AEs in the studied population. Our choice of restricting the investi-
gation to only the intensive phase treatment did not allow the investigation of the chronic AEs
that might have appeared during the continuation phase treatment. However, despite these
limitations, our findings have generated information with implications for policy and practice,
mainly at the level of management of the AEs in hospital settings and ambulatory care, the
need for safer drugs, management of co-morbidity and under-reporting of AEs to the NPC.
Fig 4. Duration of ADRs amongMDR-TB patients admitted to in-patient care, Nigeria, 2012–2013.
doi:10.1371/journal.pone.0120161.g004
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Management of AEs in hospital settings
Our study and others [19, 20] suggest that gastro-intestinal, neurological, ototoxic and psychi-
atric AEs are likely to be experienced by many patients as they embark on the intensive phase
treatment using the standard regimen. To minimize the adverse impact of AEs on treatment
adherence, it is important that health staff are adequately trained on their recognition and
management. Such training should include how to provide concise pretreatment counseling to
patients on possible AEs of treatment [34]. It is also important that medications for managing
Table 4. Association between AEs, sex, age and body weight among MDR-TB patients admitted to in-patient care, Nigeria, 2012–2013.
Variable AE No AE Adjusted OR (95% CI)* Adjusted p value*
TOTAL 203 (44) 257 (56) - -
Treatment center
MHY 40 (41) 57 (59) 1 -
DLHMH 41 (80) 10 (20) 5.8 (2.6–12.9) <0.001
GCH 40 (49) 42 (51) 1.4 (0.8–2.5) 0.3
IDH 7 (18) 33 (83) 0.3 (0.1–0.8) 0.02
JUTH 7 (24) 22 (76) 0.4 (0.2–1.1) 0.09
NTBLTC 3 (7) 38 (93) 0.1 (0.04–0.4) 0.001
UCH 31 (45) 38 (55) 1.1 (0.6–2.0) 0.8
UPTH 33 (87) 5 (13) 8.6 (3.0–24.1) <0.001
UUTH 1 (8) 12 (92) 0.1 (0.01–0.9) 0.04
Sex
Male 118 (41) 167 (59) 1 -
Female 83 (48) 89 (52) 1.2 (0.7–1.9) 0.5
Not registered 2 (67) 1 (33) - -
Age (Years)
<15 1 (17) 5 (83) 0.2 (0.01–3.5) 0.2
15–25 34 (43) 45 (57) 1.2 (0.6–2.2) 0.6
26–35 79 (42) 108 (58) 1 -
36–45 48 (49) 50 (51) 1.4 (0.8–2.4) 0.3
46–55 24 (40) 36 (60) 0.6 (0.3–1.2) 0.1
56–65 14 (61) 9 (39) 1.8 (0.7–4.8) 0.3
>65 2 (40) 3 (60) 0.9 (0.1–9.1) 0.9
Not recorded 1 (50) 1 (50) - -
Weight (Kg)
<2525–30 2 (33)4 (100) 4 (67)0 1.0 (0.2–5.9)- 0.99-
31–60 141 (40) 214 (60) 1 -
61–90 56 (60) 38 (40) 2.0 (1.2–3.4) 0.008
Not recorded 0 1 (100) - -
HIV status
Negative 182 (44) 231 (56) 1 -
Positive 21 (45) 26 (55) 1.7 (0.8–3.3) 0.2
* Adjusted Odds Ratio and p-value (Wald’s test) based on multivariate logistic regression using a stepwise backward elimination approach.
Note: Treatment centers: DL HMH = Dr. Lawrence Henshaw Memorial Hospital, Calabar; GCH = General Chest Hospital, Ibadan; IDH = Infectious Disease
Hospital, Kano; JUTH = Jos University Teaching Hospital, Jos; MHY = Mainland Hospital, Yaba; NTBLCT = National Tuberculosis and Leprosy Training
Center; UCH = University College Hospital, Ibadan; UPTH = University of Port Harcourt Teaching Hospital; UUTH = University of Uyo Teaching Hospital,
Uyo.
doi:10.1371/journal.pone.0120161.t004
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AEs should be ordered concurrently with the ordering of SLDs to facilitate timely and adequate
treatment of such AEs. However, limitation of funds can hinder the stocking of all ancillary
drugs in addition to the SLDs: our findings can help guide which drugs to procure as a matter
of priority.
Management of AEs in ambulatory care
The NTBLCP currently manages the intensive phase of all MDR-TB patients in an inpatient
model [30]. In not a distant future, Nigeria may transit to the ambulatory care model where pa-
tients are treated in the community in an effort to scale up patients’ recruitment. The delays
caused by the limited inpatient capacity potentially increase the rate of TB mortality in the
country. However, the magnitude and severity of AEs reported in this study suggest that the
Federal Government needs to match the proposed transition with the scaling up of care for pa-
tient safety. Some of the severe, debilitating and fatal AEs reported in this study are better man-
aged in specialist hospitals where qualified health professionals and services are readily
available. An effective referral system for transferring patients from the communities to the
hospitals needs to be in place once the community model of care commences. It is only then
patients suffering from the AEs will have access to qualitative care.
The need for safer drugs with shorter duration of treatment
The wide range of AEs reported in this study has elaborated and refined the well-known and
dramatic toxicity of SLDs frequently reported in studies ([3, 4, 19] and [20]). Our findings sup-
port the call for safer and modified regimens, which the global plan to “Stop TB, 2011–2015”
has emphasized [35]. Fortunately, there is an emerging body of studies highlighting the safety
of some newer drugs or different combinations of existing drugs over the current SLDs. Exam-
ples are the new drug delamanid—a nitro-dihydro-imidazooxazole class of compounds—or
the combination, nitroimidazo-oxazine, (coded as PA-824), moxifloxacin and pyrazinamide
[36,37].
Some of the newer drugs have not been approved by the WHO but the real limitation is
their cost. One tablet of delamanid 25mg was sold at US$295.00 in the open market as of 12th
June, 2014 [38], while a packet of 100 tablets of Levofloxacin 500mg sold between US$ 12:00
and US$16:00 through the Global Drug Facility (GDF) [39]. Since the newer drugs are still
under patent, which may not allow cheaper generic brands to be manufactured, the Federal
Government may need to sign commercial agreements with the manufacturers for the produc-
tion of the generic brands. Additionally, the GFATM and other funding agencies need to in-
crease funding for the MDR-TB program in Nigeria to enable the procurement of the newer
drugs when finally approved.
Management of co-morbidity
Drug interactions and AEs have been a major concern in treating MDR-TB patients who are
concurrently infected with the Human Immunodeficiency Virus (HIV). One study reported
that the side-effects of TB chemotherapy is magnified in patients with concurrent HIV treat-
ment [40]. However, our study and others’ ([19, 20] and [32]) did not observe significant dif-
ference in the risk of AEs between HIV infected and non-HIV infected MDR-TB patients.
Thus, the concern for AEs should not discourage the treatment of patients with the HIV/
MDR-TB co-morbidity, although the drug-drug interactions still have to be considered.
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Underreporting of adverse events to the National Pharmacovigilance
Center
Local drug safety surveillance for the protection of human populations from the dangers of
AEs depends on an efficient reporting of ICSRs to central coordinating bodies like the NPC
[41]. However, our evidence and that of other studies [15–18, 28] suggest a significant under-
reporting of AEs to the NPC, as evidenced by the major differences in AE reporting between
the treatment centers. We recommend the standardization of training so that all treatment cen-
ters can monitor, treat and report AEs to the NPC. Some local studies argued that lack of ca-
pacity is the primary factor inhibiting the reporting of the AEs [16–18]. Osakwe et al [28]
found correlation between the training of health staff and reporting of AEs by health workers.
Nigeria also needs to adopt the measures used in some countries to improve the reporting of
AEs to the NPC. In Sweden, France and Italy, reporting of AEs is compulsory [42]. In the USA
and more recently in some other countries, patients can also report directly to the spontaneous
reporting system (SRS) [43].
The need to increase patient enrollment into care
Almost 90% of the patients completed the intensive phase treatment and were alive at the time
the data were collected; 21 (6%) patients died of TB while on treatment and 4 (1%) absconded
without being discharged. In a similar study, Oladimeji et al reported a high rate of MDR-TB
patient survival, “no loss to follow up” and the death of only 24 patients while on the intensive
phase treatment [30]. The MDR-TB program may be doing well in Nigeria, but, there is need
to match the high quality care with high patient enrollment, which appears to be far less than
the WHO annual target of enrolling 3600 patients.
In conclusion, the participants experienced a wide range of AEs with a number of fatalities,
thereby supporting existing evidence that SLDs are toxic drugs, demanding close monitoring
of the patients. Further research is needed to assess the associations between the AEs and
treatment outcomes.
We recommend early identification and prompt management of AEs. A standardized re-
porting of all AEs at all levels of healthcare, including the community should become a priority.
We advocate for safer regimens for drug-resistant TB with the shortest duration possible.
These are the minimum and immediate actions the government must take to protect the citi-
zens from the harmful consequences of AEs.
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